Impact of psm-mec in the mobile genetic element on the clinical characteristics and outcome of SCCmec-II methicillin-resistant Staphylococcus aureus bacteraemia in Japan

Tetsuji Aoyagi, C. Kaito, K. Sekimizu, Y. Omae, Y. Saito, H. Mao, S. Inomata, M. Hatta, S. Endo, H. Kanamori, Y. Gu, K. Tokuda, H. Yano, M. Kitagawa, M. Kaku

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Over-expression of alpha-phenol-soluble modulins (PSMs) results in high virulence of community-associated methicillin-resistant Staphylococcus aureus (MRSA). The psm-mec gene, located in the mobile genetic element SCCmec-II, suppresses PSMαs production. Fifty-two patients with MRSA bacteraemia were enrolled. MRSA isolates were evaluated with regard to the psm-mec gene sequence, bacterial virulence, and the minimum inhibitory concentration (MIC) of vancomycin and teicoplanin. Fifty-one MRSA isolates were classified as SCCmec-II, and 10 had one point mutation in the psm-mec promoter. We compared clinical characteristics and outcomes between mutant MRSA and wild-type MRSA. Production of PSMα3 in mutant MRSA was significantly increased, but biofilm formation was suppressed. Wild-type MRSA caused more catheter-related bloodstream infections (30/41 vs. 3/10, p 0.0028), whereas mutant MRSA formed more deep abscesses (4/10 vs. 3/41, p 0.035). Bacteraemia caused by mutant MRSA was associated with reduced 30-day mortality (1/10 vs. 13/41, p 0.25), although this difference was not significant. The MIC90 of teicoplanin was higher for wild-type MRSA (1.5 mg/L vs. 1 mg/L), but the MIC of vancomycin was not different between the two groups. The 30-day mortality of MRSA with a high MIC of teicoplanin (≥1.5 mg/L) was higher than that of strains with a lower MIC (≤0.75 mg/L) (6/10 vs. 6/33, p 0.017). Mutation of the psm-mec promoter contributes to virulence of SCCmec-II MRSA, and the product of psm-mec may determine the clinical characteristics of bacteraemia caused by SCCmec-II MRSA, but it does not affect mortality.

Original languageEnglish
Pages (from-to)912-919
Number of pages8
JournalClinical Microbiology and Infection
Volume20
Issue number9
DOIs
Publication statusPublished - Sep 1 2014
Externally publishedYes

Fingerprint

Interspersed Repetitive Sequences
Methicillin-Resistant Staphylococcus aureus
Bacteremia
Japan
Microbial Sensitivity Tests
Teicoplanin
Virulence
Vancomycin
Mortality
Bacterial Genes
Catheter-Related Infections
Biofilms
Point Mutation

Keywords

  • MRSA
  • Clinical characteristics
  • Phenol-soluble modulins
  • psm-mec mutation
  • Teicoplanin
  • Vancomycin

ASJC Scopus subject areas

  • Microbiology (medical)
  • Infectious Diseases

Cite this

Impact of psm-mec in the mobile genetic element on the clinical characteristics and outcome of SCCmec-II methicillin-resistant Staphylococcus aureus bacteraemia in Japan. / Aoyagi, Tetsuji; Kaito, C.; Sekimizu, K.; Omae, Y.; Saito, Y.; Mao, H.; Inomata, S.; Hatta, M.; Endo, S.; Kanamori, H.; Gu, Y.; Tokuda, K.; Yano, H.; Kitagawa, M.; Kaku, M.

In: Clinical Microbiology and Infection, Vol. 20, No. 9, 01.09.2014, p. 912-919.

Research output: Contribution to journalArticle

Aoyagi, T, Kaito, C, Sekimizu, K, Omae, Y, Saito, Y, Mao, H, Inomata, S, Hatta, M, Endo, S, Kanamori, H, Gu, Y, Tokuda, K, Yano, H, Kitagawa, M & Kaku, M 2014, 'Impact of psm-mec in the mobile genetic element on the clinical characteristics and outcome of SCCmec-II methicillin-resistant Staphylococcus aureus bacteraemia in Japan', Clinical Microbiology and Infection, vol. 20, no. 9, pp. 912-919. https://doi.org/10.1111/1469-0691.12575
Aoyagi, Tetsuji ; Kaito, C. ; Sekimizu, K. ; Omae, Y. ; Saito, Y. ; Mao, H. ; Inomata, S. ; Hatta, M. ; Endo, S. ; Kanamori, H. ; Gu, Y. ; Tokuda, K. ; Yano, H. ; Kitagawa, M. ; Kaku, M. / Impact of psm-mec in the mobile genetic element on the clinical characteristics and outcome of SCCmec-II methicillin-resistant Staphylococcus aureus bacteraemia in Japan. In: Clinical Microbiology and Infection. 2014 ; Vol. 20, No. 9. pp. 912-919.
@article{2fb514e21f654cdd97ec1e8e511e24d2,
title = "Impact of psm-mec in the mobile genetic element on the clinical characteristics and outcome of SCCmec-II methicillin-resistant Staphylococcus aureus bacteraemia in Japan",
abstract = "Over-expression of alpha-phenol-soluble modulins (PSMs) results in high virulence of community-associated methicillin-resistant Staphylococcus aureus (MRSA). The psm-mec gene, located in the mobile genetic element SCCmec-II, suppresses PSMαs production. Fifty-two patients with MRSA bacteraemia were enrolled. MRSA isolates were evaluated with regard to the psm-mec gene sequence, bacterial virulence, and the minimum inhibitory concentration (MIC) of vancomycin and teicoplanin. Fifty-one MRSA isolates were classified as SCCmec-II, and 10 had one point mutation in the psm-mec promoter. We compared clinical characteristics and outcomes between mutant MRSA and wild-type MRSA. Production of PSMα3 in mutant MRSA was significantly increased, but biofilm formation was suppressed. Wild-type MRSA caused more catheter-related bloodstream infections (30/41 vs. 3/10, p 0.0028), whereas mutant MRSA formed more deep abscesses (4/10 vs. 3/41, p 0.035). Bacteraemia caused by mutant MRSA was associated with reduced 30-day mortality (1/10 vs. 13/41, p 0.25), although this difference was not significant. The MIC90 of teicoplanin was higher for wild-type MRSA (1.5 mg/L vs. 1 mg/L), but the MIC of vancomycin was not different between the two groups. The 30-day mortality of MRSA with a high MIC of teicoplanin (≥1.5 mg/L) was higher than that of strains with a lower MIC (≤0.75 mg/L) (6/10 vs. 6/33, p 0.017). Mutation of the psm-mec promoter contributes to virulence of SCCmec-II MRSA, and the product of psm-mec may determine the clinical characteristics of bacteraemia caused by SCCmec-II MRSA, but it does not affect mortality.",
keywords = "MRSA, Clinical characteristics, Phenol-soluble modulins, psm-mec mutation, Teicoplanin, Vancomycin",
author = "Tetsuji Aoyagi and C. Kaito and K. Sekimizu and Y. Omae and Y. Saito and H. Mao and S. Inomata and M. Hatta and S. Endo and H. Kanamori and Y. Gu and K. Tokuda and H. Yano and M. Kitagawa and M. Kaku",
year = "2014",
month = "9",
day = "1",
doi = "10.1111/1469-0691.12575",
language = "English",
volume = "20",
pages = "912--919",
journal = "Clinical Microbiology and Infection",
issn = "1198-743X",
publisher = "Elsevier Limited",
number = "9",

}

TY - JOUR

T1 - Impact of psm-mec in the mobile genetic element on the clinical characteristics and outcome of SCCmec-II methicillin-resistant Staphylococcus aureus bacteraemia in Japan

AU - Aoyagi, Tetsuji

AU - Kaito, C.

AU - Sekimizu, K.

AU - Omae, Y.

AU - Saito, Y.

AU - Mao, H.

AU - Inomata, S.

AU - Hatta, M.

AU - Endo, S.

AU - Kanamori, H.

AU - Gu, Y.

AU - Tokuda, K.

AU - Yano, H.

AU - Kitagawa, M.

AU - Kaku, M.

PY - 2014/9/1

Y1 - 2014/9/1

N2 - Over-expression of alpha-phenol-soluble modulins (PSMs) results in high virulence of community-associated methicillin-resistant Staphylococcus aureus (MRSA). The psm-mec gene, located in the mobile genetic element SCCmec-II, suppresses PSMαs production. Fifty-two patients with MRSA bacteraemia were enrolled. MRSA isolates were evaluated with regard to the psm-mec gene sequence, bacterial virulence, and the minimum inhibitory concentration (MIC) of vancomycin and teicoplanin. Fifty-one MRSA isolates were classified as SCCmec-II, and 10 had one point mutation in the psm-mec promoter. We compared clinical characteristics and outcomes between mutant MRSA and wild-type MRSA. Production of PSMα3 in mutant MRSA was significantly increased, but biofilm formation was suppressed. Wild-type MRSA caused more catheter-related bloodstream infections (30/41 vs. 3/10, p 0.0028), whereas mutant MRSA formed more deep abscesses (4/10 vs. 3/41, p 0.035). Bacteraemia caused by mutant MRSA was associated with reduced 30-day mortality (1/10 vs. 13/41, p 0.25), although this difference was not significant. The MIC90 of teicoplanin was higher for wild-type MRSA (1.5 mg/L vs. 1 mg/L), but the MIC of vancomycin was not different between the two groups. The 30-day mortality of MRSA with a high MIC of teicoplanin (≥1.5 mg/L) was higher than that of strains with a lower MIC (≤0.75 mg/L) (6/10 vs. 6/33, p 0.017). Mutation of the psm-mec promoter contributes to virulence of SCCmec-II MRSA, and the product of psm-mec may determine the clinical characteristics of bacteraemia caused by SCCmec-II MRSA, but it does not affect mortality.

AB - Over-expression of alpha-phenol-soluble modulins (PSMs) results in high virulence of community-associated methicillin-resistant Staphylococcus aureus (MRSA). The psm-mec gene, located in the mobile genetic element SCCmec-II, suppresses PSMαs production. Fifty-two patients with MRSA bacteraemia were enrolled. MRSA isolates were evaluated with regard to the psm-mec gene sequence, bacterial virulence, and the minimum inhibitory concentration (MIC) of vancomycin and teicoplanin. Fifty-one MRSA isolates were classified as SCCmec-II, and 10 had one point mutation in the psm-mec promoter. We compared clinical characteristics and outcomes between mutant MRSA and wild-type MRSA. Production of PSMα3 in mutant MRSA was significantly increased, but biofilm formation was suppressed. Wild-type MRSA caused more catheter-related bloodstream infections (30/41 vs. 3/10, p 0.0028), whereas mutant MRSA formed more deep abscesses (4/10 vs. 3/41, p 0.035). Bacteraemia caused by mutant MRSA was associated with reduced 30-day mortality (1/10 vs. 13/41, p 0.25), although this difference was not significant. The MIC90 of teicoplanin was higher for wild-type MRSA (1.5 mg/L vs. 1 mg/L), but the MIC of vancomycin was not different between the two groups. The 30-day mortality of MRSA with a high MIC of teicoplanin (≥1.5 mg/L) was higher than that of strains with a lower MIC (≤0.75 mg/L) (6/10 vs. 6/33, p 0.017). Mutation of the psm-mec promoter contributes to virulence of SCCmec-II MRSA, and the product of psm-mec may determine the clinical characteristics of bacteraemia caused by SCCmec-II MRSA, but it does not affect mortality.

KW - MRSA

KW - Clinical characteristics

KW - Phenol-soluble modulins

KW - psm-mec mutation

KW - Teicoplanin

KW - Vancomycin

UR - http://www.scopus.com/inward/record.url?scp=84908030409&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84908030409&partnerID=8YFLogxK

U2 - 10.1111/1469-0691.12575

DO - 10.1111/1469-0691.12575

M3 - Article

C2 - 24476401

AN - SCOPUS:84908030409

VL - 20

SP - 912

EP - 919

JO - Clinical Microbiology and Infection

JF - Clinical Microbiology and Infection

SN - 1198-743X

IS - 9

ER -